---
title: "Rinvoq (upadacitinib) in rheumatoid arthritis: Safety questions"
description: "Safety questions on Rinvoq (upadacitinib) in rheumatoid arthritis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Monitoring, Safety evidence, and Infection precautions. Questions: When should RINVOQ be delayed or interrupted for lab results or infections? What are RINVOQ long-term safety rates in rheumatoid arthritis (infections, cancer, heart events, clots)? Does RINVOQ require TB testing before and during treatment? Does RINVOQ raise the risk of infections, death, cancer, heart events, or blood clots (boxed warning)? 4 further questions follow. 8 questions quoted from 5 sources."
canonical: "https://www.evicenter.com/medical-information/rinvoq--rheumatoid-arthritis/safety"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Rinvoq (upadacitinib) in rheumatoid arthritis: Safety questions

Manufacturer: AbbVie Inc.  
Prescribing information: [Rinvoq](https://www.rinvoqhcp.com/prescribinginfo)

## Monitoring

<a id="rinvoq-lab-interruption"></a>

### When should RINVOQ be delayed or interrupted for lab results or infections?

> “TREATMENT WITH RINVOQ SHOULD NOT BE INITIATED, OR SHOULD BE INTERRUPTED IF:
>
> Absolute neutrophil count
> <1000 cells/mm<sup>3</sup>*
>
> Absolute lymphocyte
> count <500 cells/mm<sup>3</sup>*
>
> Hemoglobin levels
> <8 g/dL*
>
> Liver enzyme elevations
> and a drug-induced liver
> injury is suspected*
>
> Patient has or develops
> a serious or
> opportunistic infection*
>
> *Treatment can be initiated or restarted after levels return above specified values, drug-induced liver injury diagnosis is excluded, or infection is controlled.”

Source: [RINVOQ: RINVOQ® (upadacitinib) Dosing for RA, PsA, AS, nr-axSpA, and GCA, captured 2026-11-08](https://www.rinvoqhcp.com/rheumatology/dosing-lab-monitoring#:~:text=TREATMENT%20WITH%20RINVOQ%20SHOULD%20NOT,excluded%2C%20or%20infection%20is%20controlled.)

<a id="rinvoq-lab-monitoring"></a>

### What lab monitoring does RINVOQ require?

> “Neutropenia
> Treatment with RINVOQ was associated with an increased incidence of neutropenia (absolute neutrophil count [ANC] <1000 cells/mm<sup>3</sup>). Treatment with RINVOQ is not recommended in patients with an ANC <1000 cells/mm<sup>3</sup>. Evaluate neutrophil counts at baseline and thereafter according to routine patient management.
>
> Lymphopenia
> Absolute lymphocyte counts (ALC) <500 cells/mm<sup>3</sup> were reported in RINVOQ-treated patients. Treatment with RINVOQ is not recommended in patients with an ALC <500 cells/mm<sup>3</sup>. Evaluate at baseline and thereafter according to routine patient management.
>
> Anemia
> Decreases in hemoglobin levels to <8 g/dL were reported in RINVOQ-treated patients. Treatment should not be initiated or should be interrupted in patients with hemoglobin levels <8 g/dL. Evaluate at baseline and thereafter according to routine patient management.
>
> Lipids
> Treatment with RINVOQ was associated with increases in lipid parameters, including total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol. Manage patients according to clinical guidelines for the management of hyperlipidemia. Evaluate patients 12 weeks after initiation of treatment and thereafter according to the clinical guidelines for hyperlipidemia.
>
> Liver enzyme elevations
> Treatment with RINVOQ was associated with increased incidence of liver enzyme elevation compared to placebo. Evaluate at baseline and thereafter according to routine patient management. Prompt investigation of the cause of liver enzyme elevation is recommended to identify potential cases of drug-induced liver injury. If increases in aspartate aminotransferase (AST) or alanine aminotransferase (ALT) are observed during routine patient management and drug-induced liver injury is suspected, RINVOQ should be interrupted until this diagnosis is excluded.”

Source: [RINVOQ: RINVOQ® (upadacitinib) Dosing for RA, PsA, AS, nr-axSpA, and GCA, captured 2026-11-08](https://www.rinvoqhcp.com/rheumatology/dosing-lab-monitoring#:~:text=Neutropenia,until%20this%20diagnosis%20is%20excluded.)

## Safety evidence

<a id="rinvoq-safety-exposure"></a>

### What are RINVOQ long-term safety rates in rheumatoid arthritis (infections, cancer, heart events, clots)?

> “~9.5 YEARS MAXIMUM exposure in RA (~4.2 years median) to RINVOQ 15 mg as of 08/2025<sup>§</sup>
>
> >12,900 patient-years of exposure to RINVOQ 15 mg in RA”

Source: [RINVOQ: RINVOQ® (upadacitinib) for Rheumatoid Arthritis, captured 2026-11-08](https://www.rinvoqhcp.com/rheumatoid-arthritis#:~:text=~9.5%20YEARS%20MAXIMUM%20exposure%20in,RINVOQ%2015%20mg%20in%20RA)

> “RA Phase 3 Program AEs<sup>4,7-9</sup>*
> Any RINVOQ 15 mg QD<sup>†</sup>
>
> Data as of August 15, 2025<sup>4</sup>
> TEAEs of Special Interest<sup>‡</sup>
> (E/100 PYs unless otherwise stated)
>
> 2.8 yrs. max.
> exposure
> (1.4 yrs. median)
> Data as of November 14, 2018
> n=2630, PYs=3446.2
>
> ~6.5 yrs. max.
> exposure
> (~4 yrs. median)
> Data as of August 15, 2022
> n=3209, PYs=10782.7
>
> ~9.5 yrs. max.
> exposure
> (-4.2 yrs. median)
> n=3209, PYs=12909.0
>
> INFECTIONS	 	 	 	
> Serious infections	3.5	3.6	3.5
> Active tuberculosis (TB)	0.1	<0.1	<0.1
> Opportunistic infection (excluding TB, herpes zoster, and oral candidiasis)	0.3	0.3	0.2
> Herpes zoster	3.5	3.2	3.0
> MALIGNANCY<sup>a</sup>	 	 	 	
> Malignancy (excluding NMSC)	0.8	0.7	0.7
> Lymphoma	<0.1	<0.1	<0.1
> NMSC	0.3	0.4	0.4
> CARDIOVASCULAR EVENTS<sup>a</sup>	 	 	 	
> Adjudicated VTE<sup>b</sup>	0.6	0.4	0.4
> Adjudicated MACE<sup>c</sup>	0.6	0.3	0.4
> GASTROENTEROLOGICAL EVENTS<sup>a</sup>	 	 	 	
> Adjudicated GI perforations	0.1	<0.1	<0.1”

Source: [RINVOQ: RINVOQ® (upadacitinib) Safety Data for RA, PsA, AS, nr-axSpA, and GCA, captured 2026-11-08](https://www.rinvoqhcp.com/rheumatology/safety#:~:text=RA%20Phase%203%20Program,%3C0.1)

> “Adverse reaction rates observed in clinical trials and LTE studies may not predict the rates observed in clinical practice.”

Source: [RINVOQ: RINVOQ® (upadacitinib) Safety Data for RA, PsA, AS, nr-axSpA, and GCA, captured 2026-11-08](https://www.rinvoqhcp.com/rheumatology/safety#:~:text=Adverse%20reaction%20rates%20observed%20in%20clinical%20trials%20and,rates%20observed%20in%20clinical%20practice.)

Note: The long-term table prints "(-4.2 yrs. median)" for the August 2025 data cut; the rheumatoid arthritis overview page states ~4.2 years median for the same cut.

## Infection precautions

<a id="rinvoq-tb-screening"></a>

### Does RINVOQ require TB testing before and during treatment?

> “Active tuberculosis (TB), which may present with pulmonary or extrapulmonary disease. Test patients for latent TB before RINVOQ use and during therapy. Consider treatment for latent TB infection prior to RINVOQ use.”

Source: [RINVOQ: RINVOQ® (upadacitinib) Dosing for RA, PsA, AS, nr-axSpA, and GCA, captured 2026-11-08](https://www.rinvoqhcp.com/rheumatology/dosing-lab-monitoring#:~:text=Active%20tuberculosis%20%28TB%29%2C%20which%20may,infection%20prior%20to%20RINVOQ%20use.)

> “Carefully consider the risks and benefits of treatment with RINVOQ prior to initiating therapy in patients with chronic or recurrent infection. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with RINVOQ, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.”

Source: [RINVOQ: RINVOQ® (upadacitinib) Dosing for RA, PsA, AS, nr-axSpA, and GCA, captured 2026-11-08](https://www.rinvoqhcp.com/rheumatology/dosing-lab-monitoring#:~:text=Carefully%20consider%20the%20risks%20and,infection%20prior%20to%20initiating%20therapy.)

## Safety

<a id="rinvoq-boxed-warning"></a>

### Does RINVOQ raise the risk of infections, death, cancer, heart events, or blood clots (boxed warning)?

> “RINVOQ has a Boxed Warning on Serious Infections, Mortality, Malignancy, Major Adverse Cardiovascular Events, and Thrombosis.”

Source: [RINVOQ: RINVOQ® (upadacitinib) for Rheumatoid Arthritis, captured 2026-11-08](https://www.rinvoqhcp.com/rheumatoid-arthritis#:~:text=RINVOQ%20has%20a%20Boxed%20Warning,Adverse%20Cardiovascular%20Events%2C%20and%20Thrombosis.)

> “Serious Infections: RINVOQ-treated patients are at increased risk of serious bacterial (including tuberculosis [TB]), fungal, viral, and opportunistic infections leading to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants, such as methotrexate or corticosteroids.
>
> Mortality: A higher rate of all-cause mortality, including sudden cardiovascular (CV) death, was observed with a Janus kinase inhibitor (JAKi) in a study comparing another JAKi with tumor necrosis factor (TNF) blockers in rheumatoid arthritis (RA) patients ≥50 years with ≥1 CV risk factor.
>
> Malignancies: Malignancies have occurred in RINVOQ-treated patients. A higher rate of lymphomas and lung cancer (in current or past smokers) was observed with another JAKi when compared with TNF blockers in RA patients.
>
> Major Adverse Cardiovascular Events: A higher rate of CV death, myocardial infarction, and stroke was observed with a JAKi in a study comparing another JAKi with TNF blockers in RA patients ≥50 years with ≥1 CV risk factor. History of smoking increases risk.
>
> Thromboses: Deep venous thrombosis, pulmonary embolism, and arterial thrombosis have occurred in patients treated for inflammatory conditions with JAK inhibitors, including RINVOQ. A higher rate of thrombosis was observed with another JAKi when compared with TNF blockers in RA patients.”

Source: [RINVOQ: RINVOQ® (upadacitinib) Efficacy for Rheumatoid Arthritis, captured 2026-11-08](https://www.rinvoqhcp.com/rheumatoid-arthritis/efficacy#:~:text=Serious%20Infections%3A%20RINVOQ%2Dtreated%20patients%20are,another%20JAKi%20when%20compared%20with%20TNF%20blockers%20in%20RA%20patients.)

Note: The higher rates of death, lymphoma and lung cancer, major cardiovascular events, and thrombosis in the boxed warning were observed with another JAK inhibitor compared with TNF blockers.

<a id="rinvoq-ra-side-effects"></a>

### What are the most common RINVOQ side effects in rheumatoid arthritis?

> “Most Common Adverse Reactions From SELECT-BEYOND, SELECT-NEXT, and SELECT-COMPARE (12 Weeks)<sup>1</sup>
>
> Adverse reactions reported in ≥1% of moderate to severe rheumatoid arthritis patients treated with RINVOQ 15 mg pooled from the placebo-controlled studies.
>
> ADVERSE REACTION	
> Placebo<sup>a</sup>
> n=1042 (%)
>
> RINVOQ 15 mg QD<sup>a</sup>
> n=1035 (%)
>
> Upper respiratory tract infection (URTI)<sup>b</sup>	9.5	13.5
> Nausea	2.2	3.5
> Cough	1.0	2.2
> Pyrexia	0	1.2”

Source: [RINVOQ: RINVOQ® (upadacitinib) Safety Data for RA, PsA, AS, nr-axSpA, and GCA, captured 2026-11-08](https://www.rinvoqhcp.com/rheumatology/safety#:~:text=Most%20Common%20Adverse%20Reactions%20From%20SELECT%2DBEYOND%2C,1.2)

> “In the placebo-controlled studies SELECT-BEYOND, SELECT-NEXT, and SELECT-COMPARE through 12/14 weeks, infections were reported in 20.9% of patients treated with placebo and 27.4% in patients treated with RINVOQ 15 mg<sup>10</sup>
> In the 12-month exposure dataset, the incident rate of infection was 83.8 per 100 patient-years for patients treated with RINVOQ 15 mg<sup>10</sup>”

Source: [RINVOQ: RINVOQ® (upadacitinib) Safety Data for RA, PsA, AS, nr-axSpA, and GCA, captured 2026-11-08](https://www.rinvoqhcp.com/rheumatology/safety#:~:text=INFECTIONS-,In%20the,for%20patients%20treated%20with%20RINVOQ%2015)

> “ADVERSE REACTIONS: The most common adverse reactions in RA RINVOQ clinical trials (≥1%) were upper respiratory tract infections, nausea, cough, pyrexia. Other adverse reactions reported in less than 1% of patients in the RINVOQ 15 mg group and at a higher rate than in the placebo group through Week 12 included pneumonia, herpes zoster, herpes simplex (includes oral herpes), and oral candidiasis.”

Source: [RINVOQ: RINVOQ® (upadacitinib) Safety Data for RA, PsA, AS, nr-axSpA, and GCA, captured 2026-11-08](https://www.rinvoqhcp.com/rheumatology/safety#:~:text=ADVERSE%20REACTIONS%3A%20The%20most%20common,oral%20herpes%29%2C%20and%20oral%20candidiasis.)

<a id="rinvoq-contraindications"></a>

### What are the contraindications to RINVOQ?

> “RINVOQ is contraindicated in patients with known hypersensitivity to upadacitinib or any of its excipients. If a clinically significant hypersensitivity reaction occurs, discontinue RINVOQ and institute appropriate therapy.”

Source: [RINVOQ: RINVOQ® (upadacitinib) Dosing for RA, PsA, AS, nr-axSpA, and GCA, captured 2026-11-08](https://www.rinvoqhcp.com/rheumatology/dosing-lab-monitoring#:~:text=RINVOQ%20is%20contraindicated%20in%20patients,RINVOQ%20and%20institute%20appropriate%20therapy.)

<a id="rinvoq-overdose"></a>

### What should patients do if they take too much RINVOQ?

> “If you take too much RINVOQ/RINVOQ LQ, call your healthcare provider or Poison Help line at 1-800-222-1222, or go to 
> the nearest hospital emergency room right away.”

Source: [RINVOQ: Prescribing information, page 81, captured 2026-11-08](https://www.rinvoqhcp.com/prescribinginfo#page=81)

Note: The RINVOQ prescribing information has no Overdosage section; this instruction is from the Medication Guide printed with it.

## Related pages
- [Medical information: Rinvoq (upadacitinib): Rheumatoid arthritis](https://www.evicenter.com/medical-information/rinvoq--rheumatoid-arthritis)
- [Indication](https://www.evicenter.com/medical-information/rinvoq--rheumatoid-arthritis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/rinvoq--rheumatoid-arthritis/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/rinvoq--rheumatoid-arthritis/clinical-trials)
- [Specific populations](https://www.evicenter.com/medical-information/rinvoq--rheumatoid-arthritis/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/rinvoq--rheumatoid-arthritis/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/rinvoq--rheumatoid-arthritis/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/rinvoq--rheumatoid-arthritis/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/rinvoq--rheumatoid-arthritis/access-and-coverage)
